UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2005
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-21696 22-3106987
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
26 Landsdowne Street, Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events.
In a press release dated November 16, 2005, ARIAD
Pharmaceuticals, Inc. announced interim results of an
ongoing Phase 2 clinical trial of its novel mTOR
inhibitor, AP23573, administered as a single agent, in
patients with advanced bone and soft-tissue sarcomas.
Twenty-seven percent (27%) of 188 evaluable patients
treated with AP23573 had sustained tumor regression
and/or disease stabilization. In addition, the six-month
progression-free survival (PFS) rate in AP23573-treated
patients in the first stage of the trial was 22%, which
compares favorably to historical data on soft-tissue
sarcoma patients treated with inactive chemotherapies
for whom the six-month PFS was estimated to be only 8%
(van Glabbeke et al, 2002). Almost all patients in the
current trial had failed alternative anti-cancer
treatments and had progressive disease upon entering the
trial.
A copy of the press release is filed herewith as Exhibit 99.1 and the
information contained therein is incorporated by reference into this Item
8.01 of this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
(c) The following exhibits are filed with this report
Exhibit
Number Description
------ -----------
99.1 Press release dated November 16, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARIAD Pharmaceuticals, Inc.
By: /s/Edward M. Fitzgerald
--------------------------------------
Edward M. Fitzgerald
Senior Vice President, Finance and
Corporate Operations, Chief Financial
Officer
Date: November 16, 2005
3
EXHIBIT INDEX
-------------
Exhibit
Number Description
- ------ -----------
99.1 Press release dated November 16, 2005.
4